The Indian government made several critical patent decisions over the past year. Their impact on the Indian intellectual property (IP) landscape is still evolving, with important implications for IP rights, the global pharmaceutical industry, Indian consumers, and emerging economies.
The stakes are high and reflecting on the ways in which these decisions will shape the future of industry and innovation is essential. In this column, I consider the implications of these decisions for innovative pharmaceutical manufacturers and their strategies. Continue reading “Guest column : Indian patent rulings and pharma strategies”